症状性外周动脉闭塞性疾病的最佳药物治疗及女性患者劣势:德国医保数据分析
女性OPT处方率低于男性(37.0% vs. 42.7%),患者和医疗变量差异解释了56%的差距,且该差距未随时间缩小。
要点
- 女性症状性PAOD患者OPT处方率低于男性(37.0% vs. 42.7%)。
- 女性降脂药处方率低于男性(52.4% vs. 59.9%)。
- 性别处方差距未随时间缩小,尽管总体OPT处方率呈上升趋势。
核心结论
- 女性症状性PAOD患者OPT处方率低于男性,尤其是降脂药。
研究设计与样本
- 基于德国BARMER医保数据的回顾性分析,纳入2010年1月1日至2018年6月30日因症状性PAOD住院的患者,随访至2018年底。
主要发现
- 女性既往因PAOD门诊治疗率低于男性(39.8% vs. 47.0%)。
- 女性更常因缺血性静息痛入院(13.9% vs. 10.4%),且年龄更大(74 vs. 70岁)。
- 女性降脂药处方率低于男性(52.4% vs. 59.9%),抗高血压药处方率高于男性(86.7% vs. 84.1%)。
- 女性OPT处方率低于男性(37.0% vs. 42.7%),患者和医疗变量差异解释了56%的差距。
临床怎么用
- 临床应关注女性症状性PAOD患者的最佳药物治疗,尤其是降脂药的处方。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Optimal pharmacological treatment (OPT) for peripheral arterial occlusive disease (PAOD) includes prescription of lipid lowering drugs, antithrombotics, and antihypertensives to symptomatic patients affected by intermittent claudication or chronic limb threatening ischaemia. This study sought to determine sex disparities and time trends in prescription of OPT in this population (clinicaltrials.gov NCT03909022). METHODS: Using data from the second largest insurance fund in Germany, BARMER, data on patients with an index admission for symptomatic PAOD between 1 January 2010 and 30 June 2018 with follow up until the end of 2018 were analysed. Sex disparities in post-discharge prescription status six months after index admission were tested and adjusted for patient and healthcare variables using bivariable tests and logistic regression analysis. Time trends in the prescription prevalence of OPT were analysed and tested. RESULTS: There were 83 867 patients (mean age 71.9 years and 45.8% women) eligible for inclusion in the study. When compared with men, women had lower rates of prior outpatient care for PAOD (39.8% vs. 47.0%), were admitted more often with ischaemic rest pain (13.9% vs. 10.4%) and were older (74 vs. 70 y). After discharge, women had a lower rate of prescriptions for lipid lowering drugs (52.4% vs. 59.9%), while they received antihypertensive drugs more often (86.7% vs. 84.1%). We found evidence for a lower prescription prevalence of OPT in females (37.0% vs. 42.7%). Differences in patient and healthcare variables (e.g. demographics, comorbidities, prior treatment) between women and men explained 56% of this gap. The sex prescription gap did not narrow over time despite an overall upward trend in prescription prevalence for both women and men. CONCLUSION: Although presenting older and with more severe symptoms at the index admission for PAOD, women have a lower prescription prevalence of OPT compared with men, particularly with respect to lipid lowering drugs.
引用
- Peters F, Kreutzburg T, Rieß HC, et al. Editor's Choice - Optimal Pharmacological Treatment of Symptomatic Peripheral Arterial Occlusive Disease and Evidence of Female Patient Disadvantage: An Analysis of Health Insurance Claims Data. Eur J Vasc Endovasc Surg. 2020. PMID: 32669223. doi:10.1016/j.ejvs.2020.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。